We analyzed more than 300 biomarkers in two multicenter, observational clinical trials including more than 1,200 patients across 37 sites, many of whom experienced sepsis, shock, major surgery and trauma.4 Two biomarkers stood out for assessing the risk of acute kidney injury development: TIMP-2 and IGFBP-7.
When can AKI intervention begin?
The NephroCheck Test and AKIRisk Score can help Dr. Harold Szerlip decide when to intervene earlier with patients at risk of developing acute kidney injury in order to try to prevent progression to kidney damage.
Meet the Biomarkers
The two biomarkers are involved in responses to a wide variety of tissue insults (inflammation, oxidative stress, ultraviolet radiation, drugs and toxins), and each is thought to be involved in G1 cell-cycle arrest during the earliest phases of cellular stress.5
NephroCheck AKIRisk Score: A Renal “Alarm System”
The NephroCheck Test measures TIMP-2 and IGFBP-7 in urine, providing a single quantitative result in about 20 minutes.
The NephroCheck Test Outperforms Existing Biomarkers
The NephroCheck Test exhibited an Area Under the Curve (AUC) of 0.80 for development of moderate to severe acute kidney injury within 12 hours.4
The NephroCheck Test Has Significant Ability to Discriminate Patients with Risk for AKI from Those Without
The superior discrimination of the NephroCheck Test allows for a confident result, thereby providing the clinician with a clearer, more actionable path.4
The NephroCheck Test Performance Is Consistent
A recent review in Nephrology Dialysis Transplantation shows the NephroCheck Test performance was remarkably consistent across the three large ICU studies (Sapphire, Opal and Topaz).5